Royalty Pharma said on Friday it would pay about $1.1 billion to acquire RP Management, an organization that manages its operations as the healthcare firm seeks to simplify corporate structure.

Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...

Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in ...

Alzhemier’s disease could be diagnosed up to a decade earlier after the world’s biggest study of proteins is completed. The research, which will begin in the UK this month, will aim to pinpoint how ...

On Tuesday, January 7, the FDA announced it would now be requiring GSK and Pfizer’s RSV vaccines to hold warnings of a risk ...

As for GBS itself, this neurological ailment can be severe, attacking nerves and warranting hospitalisation for weeks or ...

Companies seeking to benefit from campaign promises to cut regulations and taxes are ditching diversity and climate ...

A world leading UK Biobank study of half a million Brits could unlock the mysteries of ‘proteomics’ to prevent and cure ...

The world’s largest study of proteins circulating the human body will begin in the UK this month, with the aim of pinpointing ...

NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ...

Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.